FDA Grants CIMZIA Breakthrough Designation in High-Risk Obstetric APS
UCB disclosed that FDA granted Breakthrough Therapy Designation to certolizumab pegol for preventing placenta-mediated adverse pregnancy outcomes in pregnant patients with antiphospholipid syndrome who are persistently lupus-anticoagulant positive and have relevant prior obstetric or…
